These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26666161)

  • 1. [The trend of new drug development for the treatment of diabetes mellitus].
    Kaku K
    Nihon Rinsho; 2015 Dec; 73(12):2108-14. PubMed ID: 26666161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose-lowering drugs: balancing risks and benefits.
    The Lancet Diabetes Endocrinology
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):669. PubMed ID: 28802987
    [No Abstract]   [Full Text] [Related]  

  • 3. Liraglutide (Victoza) for type 2 diabetes.
    Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are we waiting too long for the cardiovascular outcome trials with the glucagon-like peptide-1 receptor agonists?
    Doggrell SA
    Expert Opin Drug Saf; 2015 Jun; 14(6):801-5. PubMed ID: 25891299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.
    Wu S; Sun F; Zhang Y; Yang Z; Hong T; Chen Y; Zhan S
    J Clin Pharm Ther; 2014 Feb; 39(1):7-13. PubMed ID: 24127768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicinal chemistry of glucagon-like peptide receptor agonists.
    Jones LH; Price DA
    Prog Med Chem; 2013; 52():45-96. PubMed ID: 23384666
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?
    Burgmaier M; Heinrich C; Marx N
    Diabet Med; 2013 Mar; 30(3):289-99. PubMed ID: 22804451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes].
    Salvador J; Andrada P
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():28-34. PubMed ID: 25437463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel GLP-1 receptor agonists for diabetes.
    Garber AJ
    Expert Opin Investig Drugs; 2012 Jan; 21(1):45-57. PubMed ID: 22111970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for the development of new PPAR agonists in diabetes.
    Cavender MA; Nicholls SJ; Lincoff AM
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
    Spellman CW
    J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S7-15. PubMed ID: 22267302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of diabetes mellitus. New developments and hopes].
    Verspohl EJ
    Med Monatsschr Pharm; 2005 Jun; 28(6):193-202; quiz 203. PubMed ID: 15960421
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular safety and diabetes drug development.
    Drucker DJ; Goldfine AB
    Lancet; 2011 Mar; 377(9770):977-9. PubMed ID: 21316097
    [No Abstract]   [Full Text] [Related]  

  • 15. GLP-1: physiological effects and potential therapeutic applications.
    Aaboe K; Krarup T; Madsbad S; Holst JJ
    Diabetes Obes Metab; 2008 Nov; 10(11):994-1003. PubMed ID: 18435775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing new drugs for diabetes and cardiometabolic disorders: a changing paradigm.
    Krentz AJ; Morrow L; Hompesch M
    Drugs; 2012 Sep; 72(13):1709-11. PubMed ID: 22931519
    [No Abstract]   [Full Text] [Related]  

  • 17. Bringing liraglutide to market: a CER case study.
    Oderda G; Sifford-Wilson SM
    J Manag Care Pharm; 2012 Jun; 18(5 Supp A):S12-8. PubMed ID: 22663295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current aspects of the mechanism of action of calcium antagonists in patients with diabetes mellitus].
    Kostiuk OP; Zubkova ST
    Fiziol Zh (1978); 1992; 38(3):106-11. PubMed ID: 1499754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Obes Metab; 2014 Jan; 16(1):38-47. PubMed ID: 23829656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).
    Filipski KJ
    Expert Opin Ther Pat; 2015 Jul; 25(7):819-30. PubMed ID: 25828189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.